---
document_datetime: 2025-12-08 10:50:40
document_pages: 9
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/scemblix-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: scemblix-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.9123321
conversion_datetime: 2025-12-15 02:33:20.705839
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Scemblix

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number                    | Scope                                                                                                            | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                         |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000280241 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.13 Submission of additional clinical and non-clinical studies, | 27/11/2025                          | N/A                                         |                                  | The final efficacy findings from study A2301 support the previously established efficacy of Scemblix in the third-/ and later-line setting. The |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                                       | including BE-studies. - Accepted Submission of the final report from study CABL001A2301 listed as a category 3 study in the RMP; this is a phase 3, multicenter, open-label, randomized study of oral asciminib vs bosutinib in patients with CML-CP previously treated with two or more tyrosine kinase inhibitors. The RMP version 6.0 has also been submitted.                                                                                                                                                                                                                                                      |            |            |                       | safety profile of asciminib is still considered to be generally manageable.   |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|-------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000265010 | This was an application for a group of variations. C.I.6 Change(s) to therapeutic indication(s) - C.I.6.a Addition of a new therapeutic indication or modification of an approved one - Accepted C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted A grouped application consisting of: C.I.6.a: Extension of indication to include treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic | 16/10/2025 | 17/11/2025 | SmPC, Annex II and PL | Please refer to Scientific Discussion 'Scemblix-H- C-5605-II-VR/0000265010.   |

<div style=\"page-break-after: always\"></div>

|                                       | phase (CP) for SCEMBLIX. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated accordingly. RMP version 4.2 has also been submitted. As part of the application the MAH is requesting a 1-year extension of the market protection. C.I.4: Update of sections 4.2, 4.5, 5.1, 5.2 and 5.3 of the SmPC in order to introduce a new posology regimen of 80 mg QD. The Package Leaflet is updated accordingly. RMP version 4.2 has also been submitted.   |            |            |                 |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|
| Variation type IB / EMA/VR/0000287112 | This was an application for a group of variations. A. ADMINISTRATIVE CHANGES - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted B.II.c.1 Change in the specification parameters and/or limits of an excipient - B.II.c.1.z Other changes - Accepted     | 09/10/2025 | 17/11/2025 | Annex II and PL |

<div style=\"page-break-after: always\"></div>

| parameters and/or limits of the finished product - B.II.d.1.z Change in the specification parameters and/or limits of the finished product to more accurately describe the appearance of the drug product - Accepted B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.e Site where any manufacturing operation(s) take place, except batch-release, batch control, primary and secondary packaging, for nonsterile medicinal products - Accepted B.II.b.2 Change to importer, batch release arrangements and quality control testing of the finished product - B.II.b.2.a Replacement or addition of a site where batch control/testing takes place - Accepted B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.b Primary packaging site - Accepted   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| product - B.II.b.1.a Secondary packaging site - Accepted B.II.b.2.c Replacement or addition of a manufacturer responsible for importation and/or batch release - B.II.b.2.c.2 Including batch control/testing - Accepted B.II.b.3 Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - B.II.b.3.a Minor change in the manufacturing process - Accepted B.II.b.3 Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - B.II.b.3.a Minor change in the manufacturing process - Accepted B.II.b.3 Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - B.II.b.3.a Minor change in the manufacturing process - Accepted B.II.b.3 Change in the manufacturing   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                                       | of the finished product - B.II.b.3.a Minor change in the manufacturing process - Accepted B.II.b.3 Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - B.II.b.3.a Minor change in the manufacturing process - Accepted B.II.b.4 Change in the batch size (including batch size ranges) of the finished product - B.II.b.4.b Downscaling down to 10-fold - Accepted B.II.d.2 Change in test procedure for the finished product - B.II.d.2.a Minor changes to an approved test procedure - Accepted B.II.g.4 Changes to an approved change management protocol - B.II.g.4.b Minor changes to an approved change management protocol that do not change the strategy defined in the protocol -   |            |            |             |                                                                                                                                                                                           |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000248179 | This was an application for a group of variations. C.I HUMAN AND VETERINARY MEDICINAL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 25/04/2025 | 09/07/2025 | SmPC and PL | Update of information regarding potential drug interactions of asciminib, based on 2 drug-drug interaction (DDI) studies in healthy subjects. In study CABL001A2111, co-administration of |

<div style=\"page-break-after: always\"></div>

| PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted A grouped application consisting of: C.I.4: Update of section 4.5 of the SmPC in order to add drug-drug interaction information with OATP1B substrates based on final results from study CABL001A2111; this is a phase 1, open- label, 2-period, single-sequence, drug- drug interaction study to assess the effect of asciminib on the pharmacokinetics of atorvastatin in healthy participants; the Package Leaflet is updated accordingly. C.I.4: Update of section 4.5 of the SmPC in order to add drug-drug interaction information with CYP3A4 inducing agents based on final results from study CABL001A2110; this is a phase 1, open- label, drug-drug interaction study to assess the effect of a CYP3A4 inducer, phenytoin on the pharmacokinetics of a   | asciminib at 80 mg once daily with an OATP1B, CYP3A4 and P-gp substrate (atorvastatin) increased atorvastatin AUCinf and Cmax by 14% and 24%, respectively. Clinically relevant interactions between asciminib and OATP1B substrates are unlikely to occur. In study CABL001A2110, co-administration of a single asciminib dose of 200 mg with a strong CYP3A4 inducer (phenytoin) decreased asciminib AUCinf and Cmax by 34% and 22%, respectively.   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                                       | single oral dose of 200 mg asciminib in healthy participants.                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |     |                   |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------|
| Variation type IA /                   | A. ADMINISTRATIVE CHANGES - A.4 Change in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier) - Accepted | 25/03/2025 | N/A | EMA/VR/0000261219 |
| Variation type IB / EMA/VR/0000246322 | This was an application for a group of variations. B.II.d.1 Change in the specification parameters and/or limits of the finished product - B.II.d.1.z Reduction in the testing frequency of an analysis, from routine testing to skip or periodic testing (microbial testing of finished product). - Accepted B.II.g.5 Implementation of changes foreseen in an approved change management protocol - B.II.g.5.a The implementation of the change requires no                                                             | 25/02/2025 | N/A |                   |

<div style=\"page-break-after: always\"></div>

|                     | further supportive data - Accepted   |             |
|---------------------|--------------------------------------|-------------|
| PSUR /              | - -                                  | Maintenance |
| EMA/PSUR/0000288288 |                                      |             |